Ratings Thermo Fisher Scientific Berne S.E.

Equities

TFS

US8835561023

Delayed Berne S.E. Other stock markets 17:00:02 02/04/2024 BST			5-day change	1st Jan Change
514.5 ^CHF	-0.35%		-0.35%	+19.58%

07:30am	Devyser Diagnostics AB Announces Expanded Commercial Agreement with Thermo Fisher Scientific for Post-Transplant Monitoring NGS Products	CI
06-12	Thermo Fisher Scientific Introduces Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators	CI

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company is in debt and has limited leeway for investment
With an expected P/E ratio at 35.92 and 30.81 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
THERMO FISHER SCIENTIFIC	+19.58%	218B	-
DANAHER CORPORATION	+9.90%	189B	B-
INTUITIVE SURGICAL, INC.	+26.47%	151B	B-
BOSTON SCIENTIFIC CORPORATION	+31.87%	113B	A-
SIEMENS HEALTHINEERS AG	-0.15%	64.02B	A-
EDWARDS LIFESCIENCES CORPORATION	+12.89%	52.6B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+1.85%	49.85B	B+
AGILENT TECHNOLOGIES, INC.	-6.07%	37.89B	A
GE HEALTHCARE TECHNOLOGIES INC.	-0.61%	34.92B	-
RESMED, INC.	+22.06%	31.1B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes